PLETHORA SOLUTIONS LIMITED

• ⚠

  Material uncertainty over going concern

  We draw attention to note 2 in the financial statements, which indicates that the Company is reliant on support from its Group to continue to trade. The Group that is providing support incurred a loss of approximately US$4,482,000 during the year ended 31 December 2024 and, as of that date, the Group has net current liabilities and net liabilities of approximately US$5,048,000 and US$5,901,000 respectively. These conditions indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Cooper Parry Group Limited

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“We draw attention to note 2 in the financial statements, which indicates that the Company is reliant on support from its Group to continue to trade. The Group that is providing support incurred a loss of approximately US$4,482,000 during the year ended 31 December 2024 and, as of that date, the Group has net current liabilities and net liabilities of approximately US$5,048,000 and US$5,901,000 respectively. These conditions indicate that a material uncertainty exists that may cast significant doubt on the Company's ability to continue as a going concern.”

Group structure

1. PLETHORA SOLUTIONS LIMITED · parent
   1. Plethora Pharma Solutions Limited 100% · Ireland · Activities of holding companies

Significant events

• “Wanbang Biopharmaceutical through the submission of the NDA to NMPA at the end of 2024, with approval expected 12 months thereafter.”
• “Group has "out licensed" the rights to Fortacin to Kobayashi Pharmaceutical Co., Ltd. for Japan and had received a signature payment of US$500,000 on 26 July 2024.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

6

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +271.5%

  £137,000 → £509,000

• Cash

  -72.5%

  £51,000 → £14,000

• Net assets

  +0.5%

  -£41,362,000 → -£41,161,000

• Employees

  0%

  1 → 1

• Operating profit

  +137.6%

  -£487,000 → £183,000

• Profit before tax

  +137%

  -£489,000 → £181,000

• Wages

  -4.9%

  £144,000 → £137,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers